Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LONITEN vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arteries. It reduces peripheral vascular resistance and blood pressure by hyperpolarizing vascular smooth muscle cells via activation of ATP-sensitive potassium channels.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
FDA-approved for treatment of hypertension (as a third-line agent in patients who have not responded to other antihypertensives),Off-label: treatment of androgenetic alopecia (topical formulation; oral low-dose minoxidil is also used for hair loss)
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
10 mg orally twice daily, titrated to 40 mg twice daily for hypertension; for heart failure, start at 2.5-5 mg orally twice daily, max 20 mg twice daily.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal elimination half-life: 4.2 hours (range 3.5–5.5); clinically, half-life extends to 14–23 hours after chronic dosing due to drug accumulation.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Primarily metabolized by the liver via glucuronidation (UGT1A1) to inactive metabolites; less than 20% excreted unchanged in urine.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Renal: 85% (12% unchanged, 73% as glucuronide conjugates); biliary/fecal: 3%
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
No significant plasma protein binding (<1%); binds to vasular smooth muscle tissue.
~10-20% bound to plasma proteins (primarily albumin).
1.5 L/kg (range 1.2–2.0); large Vd indicates extensive tissue binding, primarily to arteriolar smooth muscle.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral: 95% (rapidly and completely absorbed).
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
No dose adjustment needed for mild to moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), reduce dose by 50% and monitor closely.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
No specific Child-Pugh based guidelines; use with caution in severe hepatic impairment as drug may accumulate. Reduce initial dose by 50% in Child-Pugh class C.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
For hypertension: 0.1-0.2 mg/kg orally once daily, titrate to max 0.5 mg/kg/day divided every 12-24 hours, max 50 mg/day.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Start at lower end of dosing range (2.5-5 mg twice daily) due to increased sensitivity; titrate slowly. Monitor for orthostatic hypotension and renal function.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
Must be administered under close medical supervision; may cause pericardial effusion, occasionally progressing to cardiac tamponade, especially in patients with renal impairment or those on dialysis.
None
Monitor for pericardial effusion and tamponade; discontinue if effusion occurs and treat appropriately.,May cause severe fluid retention and congestive heart failure; administer with a diuretic.,Can exacerbate angina; use with caution in patients with coronary artery disease.,Hypertrichosis (excessive hair growth) is common; reversible upon discontinuation.,Monitor blood pressure closely; avoid abrupt withdrawal to prevent rebound hypertension.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to minoxidil or any component of the formulation.,Pheochromocytoma (due to risk of catecholamine release).
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Avoid high-sodium foods and excessive alcohol intake, which can exacerbate fluid retention and hypertension. No specific food interactions with minoxidil itself, but maintain a balanced diet as part of hypertension management.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
Pregnancy Category C. Fetal risks: First trimester - limited human data; animal studies show fetal resorptions and cardiovascular anomalies at high doses. Second/third trimesters - possible fetal hypotension, oligohydramnios, and hypertrichosis. Use only if benefit outweighs risk.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Excreted in breast milk; M/P ratio unknown. Avoid use while breastfeeding due to potential adverse effects (e.g., hypotension) in the infant.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
No specific dose adjustment recommended; pharmacokinetic changes in pregnancy may require titration based on maternal response and tolerability.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
Initiate at low doses (2.5 mg BID) and titrate slowly to avoid severe hypotension. Monitor for pericardial effusion, especially in patients with renal impairment. Use with a diuretic and beta-blocker to prevent reflex tachycardia and fluid retention. Abrupt discontinuation can cause rebound hypertension.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,You may experience dizziness or lightheadedness, especially when standing up; rise slowly.,Report unusual weight gain, swelling in ankles or legs, shortness of breath, or chest pain.,You may notice increased hair growth on face, arms, or back; this is reversible after stopping.,Avoid alcohol and excessive salt intake to help control blood pressure.,Use sunscreen and protective clothing as you may become more sensitive to sunlight.,Do not take over-the-counter medications without checking with your doctor.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LONITEN vs ALDOMET, answered by our medical review team.
LONITEN is a Antihypertensive that works by Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arteries. It reduces peripheral vascular resistance and blood pressure by hyperpolarizing vascular smooth muscle cells via activation of ATP-sensitive potassium channels.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LONITEN and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LONITEN is: 10 mg orally twice daily, titrated to 40 mg twice daily for hypertension; for heart failure, start at 2.5-5 mg orally twice daily, max 20 mg twice daily.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LONITEN and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LONITEN is classified as Category C. Pregnancy Category C. Fetal risks: First trimester - limited human data; animal studies show fetal resorptions and cardiovascular anomalies at high doses. Second/third trimesters -. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.